{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T09:18:24Z","timestamp":1697361504716},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2003,2,28]],"date-time":"2003-02-28T00:00:00Z","timestamp":1046390400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hautarzt"],"published-print":{"date-parts":[[2003,4]]},"DOI":"10.1007\/s00105-003-0488-3","type":"journal-article","created":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T18:52:24Z","timestamp":1478026344000},"page":"338-341","source":"Crossref","is-referenced-by-count":8,"title":["Topische Kortikoide versus Calcineurinantagonisten"],"prefix":"10.1007","volume":"54","author":[{"given":"R.","family":"Niedner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2003,2,28]]},"reference":[{"key":"0488_CR1","doi-asserted-by":"crossref","unstructured":"Bornhovd EC, Schuller E, Bieber T, Wollenberg A (2000) Immunsuppressive Makrolide und ihr Einsatz in der Dermatologie. Hautarzt 51:646\u2013654","DOI":"10.1007\/s001050051189"},{"key":"0488_CR2","unstructured":"Cornell RC, Maibach HI (1992) Clinical indications: real and assumed. In: Maibach HI, Surber C (eds) Topical corticosteroids. Karger, Basel, pp 154\u2013162"},{"key":"0488_CR3","doi-asserted-by":"crossref","unstructured":"Dissemond J, Goos M, Wagner SN (2002) Pimecrolimus (SDZ ASM 981). Aktueller Stand der Forschung. Dtsch Med Wochenschr 127:1199\u20131203","DOI":"10.1055\/s-2002-31941"},{"key":"0488_CR4","doi-asserted-by":"crossref","unstructured":"Eichenfield LF, Lucky AW, Boguniewicz M et al. (2002) Safety and efficacy of pimecrolimus (ASM 98\u00a0J) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adotescents. J Am Acad Dermatol (United States) 46:495\u2013504","DOI":"10.1067\/mjd.2002.122187"},{"key":"0488_CR5","doi-asserted-by":"crossref","unstructured":"Goldman D (2001) Tacrolimus ointment for the treatment of steroid-inctuced rosacea: a preliminary report. J Am Acad Dermatol (United States) 44:995\u2013998","DOI":"10.1067\/mjd.2001.114739"},{"key":"0488_CR6","doi-asserted-by":"crossref","unstructured":"Griffiths CE (2001) Ascomycin: an advance in the management of atopic dermatitis. Br J Dermatol (England) 144:679\u2013681","DOI":"10.1046\/j.1365-2133.2001.144004679.x"},{"key":"0488_CR7","doi-asserted-by":"crossref","unstructured":"Kaliakatsou F, Hodgson TA, Lewsey JD et al. (2002) Management of recalcitrant ulcerative oral lichen planus with topical tacrolymus. J Am Acad Dermatol (United States) 46:35\u201341","DOI":"10.1067\/mjd.2002.120535"},{"key":"0488_CR8","doi-asserted-by":"crossref","unstructured":"Luger T, Van Leent EJ, Graeber M et al. (2001) SDZ ASM 981: an emerging safe and effective treatment for atopic dermatitis. Br J Dermatol (England) 144:788\u2013794","DOI":"10.1046\/j.1365-2133.2001.04134.x"},{"key":"0488_CR9","doi-asserted-by":"crossref","unstructured":"Mrowietz U, Graeber M, Brautigam M et al. (1998) The novel ascomycin derivative SDZ ASM 981 is effective for psorasis when used topically under occlusion. Br J Dermatol 139:992\u2013996","DOI":"10.1046\/j.1365-2133.1998.02554.x"},{"key":"0488_CR10","doi-asserted-by":"crossref","unstructured":"Nghiem P, Pearson G, Langley RG (2002) Tacrolimus and pimecrolimus: from clever prokaryotes to inhibiting calcineurin and treating atopic dermatitis. J Am Acad Dermatol (United States) 46:228\u2013241","DOI":"10.1067\/mjd.2002.120942"},{"key":"0488_CR11","doi-asserted-by":"crossref","unstructured":"Reitamo S, Rustin M, Ruzicka T (2002) Efficacy and safety of tacrolimus ointment compared with hydrocortisone butyrate ointment in adult patients with atopic dermatitis. The European Tacrolimus Ointment Study Group. J Allergy Clin Immunol 109:547\u2013555","DOI":"10.1067\/mai.2002.121832"},{"key":"0488_CR12","doi-asserted-by":"crossref","unstructured":"Remitz A, Reitamo S, Erkko P et al. (1999) Tacrolimus ointment improves psoriasis in a microplaque assay. Br J Dermatol (England) 141:103\u2013107","DOI":"10.1046\/j.1365-2133.1999.02927.x"},{"key":"0488_CR13","doi-asserted-by":"crossref","unstructured":"Rozycki TW, Rogers RS, Pittelkow MR et al. (2002) Topical tacrolimus in the treatment of symptomatic oral lichen planus: a series of 13 patients. J Am Acad Dermatol (United States) 46:27\u201334","DOI":"10.1067\/mjd.2002.119648"},{"key":"0488_CR14","doi-asserted-by":"crossref","unstructured":"Schnopp C, Remling R, Mohrenschlager M et al. (2002) Topical tacrolimus (FK506) and mometasone furoate in treatment of dyshidrotic palmar eczema: a randomized, observer-blinded trial. J Am Acad Dermatol (United States) 46:73\u201377","DOI":"10.1067\/mjd.2002.117856"},{"key":"0488_CR15","unstructured":"Sch\u00f6pf E (1972) Nebenwirkungen externer Corticosteroidtherapie. Hautarzt 23:294\u2013299"},{"key":"0488_CR16","doi-asserted-by":"crossref","unstructured":"Suga Y, Tsuboi R, Hashimoto Y et al. (2000) A case of ichthyosis linearis circumflexa successfully treated with topical tacrolimus, J Am Acad Dermatol (United States) 42:520\u2013522","DOI":"10.1016\/S0190-9622(00)90234-2"},{"key":"0488_CR17","doi-asserted-by":"crossref","unstructured":"Suga Y, Hashimoto Y, Matsuba S et al. (2002) Topical tacrolimus for chronic actinic dermatitis. J Am Acad Dermatol (United States) 46:321\u2013323","DOI":"10.1067\/mjd.2002.118357"},{"key":"0488_CR18","doi-asserted-by":"crossref","unstructured":"Vente C, Reich K, Rupprecht R, Neumann C (1999) Erosive mucosal lichen planus: response to topical treatment with tacrolimus. Br J Dermatol (England) 140:338\u2013342","DOI":"10.1046\/j.1365-2133.1999.02672.x"},{"key":"0488_CR19","doi-asserted-by":"crossref","unstructured":"Weichert G, Sauder DN (2000) Efficacy of tacrolimus (FK 506) in idiopathic treatment-resistant pyoderma gangraenosum J Am Acad Dermatol. 42:304\u2013305","DOI":"10.1016\/S0190-9622(00)90149-X"},{"key":"0488_CR20","doi-asserted-by":"crossref","unstructured":"Wellington K, Jarvis B (2002) Topical pimecrolimus: a review of its clinical potential in the management of atopic dermatitis. Drugs (New Zealand) 62:817\u2013840","DOI":"10.2165\/00003495-200262050-00007"},{"key":"0488_CR21","doi-asserted-by":"crossref","unstructured":"Zabawski EJ, Costner M, Cohen JB, Cockerell CJ (2000) Tacrolimus: pharmacologv and therapeutic uses in dermatology. Int J Dermatol (United States) 39:721\u2013727","DOI":"10.1046\/j.1365-4362.2000.00731.x"}],"container-title":["Der Hautarzt"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-003-0488-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00105-003-0488-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-003-0488-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-003-0488-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T03:36:57Z","timestamp":1558582617000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00105-003-0488-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,2,28]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2003,4]]}},"alternative-id":["0488"],"URL":"https:\/\/doi.org\/10.1007\/s00105-003-0488-3","relation":{},"ISSN":["0017-8470"],"issn-type":[{"value":"0017-8470","type":"print"}],"subject":[],"published":{"date-parts":[[2003,2,28]]}}}